BIOMARIN PHARMACEUTICAL INC Insider Trading for May 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOMARIN PHARMACEUTICAL INC for May 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 22,423 | |
| May 26 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.38 | 5,000 | 441,900 | 233,564 | 238.6 K to 233.6 K (-2.10 %) |
| May 26 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 238,564 | 233.6 K to 238.6 K (+2.14 %) |
| May 19 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 27,423 | |
| May 19 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 91.73 | 5,000 | 458,650 | 233,564 | 238.6 K to 233.6 K (-2.10 %) |
| May 19 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 238,564 | 233.6 K to 238.6 K (+2.14 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 14.39 | 1,146 | 16,491 | 0 | |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 14.39 | 1,146 | 16,491 | 85,301 | 84.2 K to 85.3 K (+1.36 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 91.50 | 1,096 | 100,284 | 84,155 | 85.3 K to 84.2 K (-1.29 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 91.50 | 207 | 18,941 | 13,261 | 13.5 K to 13.3 K (-1.54 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 91.50 | 4,932 | 451,278 | 233,564 | 238.5 K to 233.6 K (-2.07 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 91.50 | 1,722 | 157,563 | 25,104 | 26.8 K to 25.1 K (-6.42 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 70.30 | 155 | 10,897 | 26,826 | 26.7 K to 26.8 K (+0.58 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 91.50 | 2,036 | 186,294 | 138,458 | 140.5 K to 138.5 K (-1.45 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 70.30 | 302 | 21,232 | 140,494 | 140.2 K to 140.5 K (+0.22 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 91.50 | 1,566 | 143,289 | 146,227 | 147.8 K to 146.2 K (-1.06 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 70.30 | 302 | 21,232 | 147,793 | 147.5 K to 147.8 K (+0.20 %) |
| May 17 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 91.50 | 1,096 | 100,284 | 50,436 | 51.5 K to 50.4 K (-2.13 %) |
| May 16 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 32,423 | |
| May 16 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.23 | 5,000 | 446,150 | 238,496 | 243.5 K to 238.5 K (-2.05 %) |
| May 16 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 243,496 | 238.5 K to 243.5 K (+2.10 %) |
| May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | M | 21.51 | 2,600 | 55,926 | 2,671 | |
| May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 93.17 | 2,600 | 242,242 | 13,468 | 16.1 K to 13.5 K (-16.18 %) |
| May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Buy | M | 21.51 | 2,600 | 55,926 | 16,068 | 13.5 K to 16.1 K (+19.31 %) |
| May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 91.17 | 4,882 | 445,092 | 13,468 | 18.4 K to 13.5 K (-26.60 %) |
| May 10 2017 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 70.30 | 270 | 18,982 | 18,350 | 18.1 K to 18.4 K (+1.49 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Option Exercise | M | 17.33 | 7,500 | 129,975 | 0 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Buy | M | 17.33 | 7,500 | 129,975 | 34,260 | 26.8 K to 34.3 K (+28.03 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 38.59 | 3,498 | 134,988 | 0 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | M | 28.23 | 988 | 27,891 | 0 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 99.00 | 3,498 | 346,302 | 51,532 | 55 K to 51.5 K (-6.36 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 38.59 | 3,498 | 134,988 | 55,030 | 51.5 K to 55 K (+6.79 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 99.00 | 988 | 97,812 | 51,532 | 52.5 K to 51.5 K (-1.88 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Buy | M | 28.23 | 988 | 27,891 | 52,520 | 51.5 K to 52.5 K (+1.92 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 38.59 | 2,500 | 96,475 | 39,844 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 100.34 | 2,500 | 250,853 | 85,251 | 87.8 K to 85.3 K (-2.85 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 38.59 | 2,500 | 96,475 | 87,751 | 85.3 K to 87.8 K (+2.93 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 70.30 | 302 | 21,232 | 85,251 | 84.9 K to 85.3 K (+0.36 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 37,423 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 42,423 | |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 93.17 | 5,000 | 465,850 | 238,496 | 243.5 K to 238.5 K (-2.05 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 243,496 | 238.5 K to 243.5 K (+2.10 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 99.00 | 5,000 | 495,000 | 238,496 | 243.5 K to 238.5 K (-2.05 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 243,496 | 238.5 K to 243.5 K (+2.10 %) |
| May 09 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 70.30 | 302 | 21,232 | 238,496 | 238.2 K to 238.5 K (+0.13 %) |
| May 04 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 96.74 | 302 | 29,215 | 51,532 | 51.8 K to 51.5 K (-0.58 %) |
| May 04 2017 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 70.30 | 302 | 21,232 | 51,834 | 51.5 K to 51.8 K (+0.59 %) |
| May 01 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.33 | 5,000 | 86,650 | 47,423 | |
| May 01 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 95.72 | 5,000 | 478,600 | 238,194 | 243.2 K to 238.2 K (-2.06 %) |
| May 01 2017 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.33 | 5,000 | 86,650 | 243,194 | 238.2 K to 243.2 K (+2.10 %) |